DCLA
CLB icon

Douglas C. Lane & Associates’s Core Laboratories CLB Stock Holding History

Douglas C. Lane & Associates’s Portfolio CLB Stock Details CLB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		$6.5M Sell
59,735
-13,972
-19% -$1.6M 0.18% 116
2015
Q3 		$7.36M Sell
73,707
-9,671
-12% -$1.05M 0.21% 111
2015
Q2 		$9.51M Sell
83,378
-5,455
-6% -$661K 0.26% 103
2015
Q1 		$9.28M Buy
88,833
+10,052
+13% +$1.07M 0.24% 103
2014
Q4 		$9.48M Buy
78,781
+12,174
+18% +$1.6M 0.26% 100
2014
Q3 		$9.75M Buy
66,607
+40,292
+153% +$6.22M 0.29% 97
2014
Q2 		$4.4M Buy
26,315
+16,171
+159% +$2.88M 0.13% 115
2014
Q1 		$2.01M Buy
10,144
+6,402
+171% +$1.21M 0.06% 127
2013
Q4 		$715K Sell
3,742
-750
-17% -$140K 0.02% 145
2013
Q3 		$760K Buy
4,492
+422
+10% +$65.5K 0.03% 136
2013
Q2 		$617K Buy
+4,070
New +$577K 0.02% 150

Other funds holding CLB

ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
WP
Wedgewood Partners St Louis, Missouri $484M AUM 14.59% 1-Year Est. Return
Kayne Anderson Rudnick Investment Management
Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return
SGA
Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return
RFC
Russell Frank Company Seattle, Washington $56.9B AUM 2.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Douglas C. Lane & Associates's CLB Position: Q4 2015 in Review

Douglas C. Lane & Associates reduced its Core Laboratories (CLB) stake by 19% in Q4 2015, selling an estimated $1.6M and leaving 59,735 shares worth $6.5M. The position accounts for 0.18% of the portfolio, ranked #116.

Douglas C. Lane & Associates first reported a position in CLB in Q2 2013 and has held it in 11 quarters since. The position peaked at $9.75M in Q3 2014. 372 funds tracked by Wall St. Rank hold CLB as of Q4 2015.

  • Douglas C. Lane & Associates held 59,735 shares of Core Laboratories worth $6.5M as of Q4 2015.
  • Douglas C. Lane & Associates sold 13,972 Core Laboratories shares in Q4 2015, an estimated $1.6M.
  • Core Laboratories made up 0.18% of Douglas C. Lane & Associates's portfolio in Q4 2015, its #116 holding.
  • Douglas C. Lane & Associates first reported a position in Core Laboratories in Q2 2013 and has held it in 11 quarters since.
  • Douglas C. Lane & Associates's Core Laboratories position peaked at $9.75M in Q3 2014.
  • 372 funds tracked by Wall St. Rank held Core Laboratories as of Q4 2015.

Based on Douglas C. Lane & Associates's 13F filing for Q4 2015, filed 25 Jan 2016.